Recommendations on the use of maternal respiratory syncytial virus (RSV) vaccines and long-acting RSV monoclonal antibodies (mAbs) to prevent severe RSV disease in infants were issued by the WHO Strategic Advisory Group of Experts (SAGE) on Immunization in September 2024 and endorsed by WHO thereafter. Evidence presented at that meeting, as well as SAGE’s conflict-of-interest assessment, can be accessed online. Separate policy recommendations on RSV vaccination for older adults will be issued at a future SAGE meeting. RSV vaccines for administration to infants older than 6 months and to toddlers are not yet licensed and are not discussed in this paper.